Moffitt logo

COVID-19 UPDATE: Moffitt is offering third doses and vaccine booster shotsLearn More

Clinical Trials Search

Clinical Trial 21061

Cancer Type: Cutaneous
Study Type: Other

Phase: N/A
Prinicipal Investigator: Jim, Heather

Call 813-745-6100
or 1-800-679-0775 Learn More

Study Title

An Examination of Patient Reported Outcomes and Predictors Among Patients with Advanced or Recurrent Melanoma Treated with Immune Checkpoint Inhibitors



Aim 1: Characterize PROs among a diverse sample of metastatic melanoma patients who have received SOC ICI treatment and compare PROs to those published from clinical trials. Aim 2: Test the proposed conceptual framework regarding the relationship between social determinants (predisposing factors), health behaviors (perpetuating factors), and PROs among metastatic melanoma patients who have received SOC ICI treatment (precipitating factor). Aim 3: Conduct qualitative interviews to explore patient perspectives of PROs, the impact of PROs on their daily lives, and further unmet needs not addressed in the questionnaire.




Inclusion Criteria

  • At least 18 years of age
  • Diagnosed with stage III or IV or recurrent metastatic melanoma
  • Have started standard of care treatment with an ICI at Moffitt at least 12 months previously
  • Be able to speak and read English
  • Be able to provide informed consent
  • Be able to participate in zoom meetings or phone interviews

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.